Conmed Corp

Conmed Corp(CNMD)股票分析

$47.580

+1.580 (+3.32%)收盤時

Loading chart…
最高
48.000
開盤
45.815
成交量加權均價
47.13
成交量
440.15K
市值
2.08B
最低
45.815
成交金額
20.75M
企業價值/稅息折舊攤銷前利潤(TTM)
7.71

CONMED Corporation is a medical technology company which provides devices and equipment for surgical procedures. Its products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Its product line consists of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine instrumentation and lower extremities instrumentation and implants, small bone, large bone and specialty-powered surgical instruments as well as imaging systems for use in minimally invasive surgical procedures and service fees related to the promotion and marketing of sports medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, smoke evacuation devices, a line of cardiac monitoring products as well as electrosurgical generators and related instruments.

AI 分析 of Conmed Corp (CNMD)

買進

Conmed Corp (CNMD) is a good buy right now, trading at $46.72, which is below the average analyst target price of $111.62. The stock has shown a strong 5-day change of +5.18% and a year-to-date change of +15.30%, indicating positive momentum. However, the main risk is its forward P/E ratio of 27.17, which suggests that the stock may be overvalued if growth does not meet expectations.

分析師評級(6)

上檔空間 +5.09%
持有
2 買進
4 持有
0 賣出
目前: 47.58
最低
41.00
平均
50.00
最高
55.00

JPMorgan

2026-07-30

目標價

$45

中性

Piper Sandler

2026-07-30

目標價

$45

中性

BMO Capital

2026-07-08

目標價

$36

Market Perform

BofA

2026-06-29

目標價

$40

落後大盤

BofA

2026-05-18

目標價

$40

中性

估值指標

Conmed Corp(CNMD)目前預期本益比為 27.17,5 年平均預期本益比為 24.50。

預期本益比

合理
5 年均值 P/E
24.50
目前P/E
27.17
高估
34.18
低估
14.82

預期 EV/EBITDA

低估
5 年均值 EV/EBITDA
13.78
目前EV/EBITDA
7.71
高估
18.30
低估
9.27

預期股價營收比

低估
5 年均值 P/S
1.97
目前P/S
0.96
高估
2.90
低估
1.05

Alphio AI 對 CNMD 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%CNMD

$71.75

情境價格

基

基準

基準 · 50%CNMD

$68.33

情境價格

悲

悲觀

悲觀 · 25%CNMD

$67.79

情境價格

持有 CNMD 的大戶

P

Paradigm Capital Management, Inc.

+ 持有CNMD

-20.64%

3個月報酬率

事件時間軸

2026-09-21 (ET)

06:30:00

Avantor Appoints Todd Garner as EVP and CFO

2026-07-29 (ET)

16:31:00

CONMED Reports Q2 Revenue of $343.5M, Exceeds Expectations

16:31:00

Raises FY26 Revenue View to $1.358B-$1.373B

2026-07-22 (ET)

07:30:00

CONMED Expands AirSeal Robotic Solution Indication

2026-07-13 (ET)

12:30:00

Major Averages Decline Amid Rising Geopolitical Tensions

資訊

CNMD 常見問題 —— 由 Alphio AI 解答

CONMED Corporation is a medical technology company which provides devices and equipment for surgical procedures. Its products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Its product line consists of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine instrumentation and lower extremities instrumentation and implants, small bone, large bone and specialty-powered surgical instruments as well as imaging systems for use in minimally invasive surgical procedures and service fees related to the promotion and marketing of sports medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, smoke evacuation devices, a line of cardiac monitoring products as well as electrosurgical generators and related instruments. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Conmed Corp (CNMD) is a good buy right now, trading at $46.72, which is below the average analyst target price of $111.62. The stock has shown a strong 5-day change of +5.18% and a year-to-date change of +15.30%, indicating positive momentum. However, the main risk is its forward P/E ratio of 27.17, which suggests that the stock may be overvalued if growth does not meet expectations.

6 analysts cover CNMD: 2 rate it Buy, 4 Hold and 0 Sell. The average price target is 50.00.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易